8:41 AM · 28 September 2022

Biogen rallies 50% in premarket on Alzheimer drug trial results

Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.

Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5

30 October 2026, 9:27 AM

Intel has come face to face with reality. A Turnaround is still a long way off.

29 October 2026, 10:25 PM

Amazon: Record-breaking operating margin outshined by capex growth

29 October 2026, 6:46 PM

Daily Summary: Bloody Thursday on Wall Street: Nasdaq Leads the Sell-Off

29 October 2026, 5:31 PM

Amazon Preview: After Microsoft and Alphabet, the Market Won’t Forgive a Disappointment

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits